Jason A.  Keyes net worth and biography

Jason Keyes Biography and Net Worth

CFO of Equillium
Jason is Chief Financial Officer at Equillium. Jason is an accomplished executive with over 16 years of experience in corporate finance and strategy within the biotechnology industry. Prior to joining Equillium, he was Executive Vice President and Chief Financial Officer of Orexigen Therapeutics, Inc. where he was responsible for finance, accounting, and investor relations. During his tenure at Orexigen, Jason led the company’s financial planning and partnership finance functions, provided business development leadership, and served as a key financial advisor to executive management in setting business and financial strategy. Before Orexigen, Jason worked at Amylin Pharmaceuticals, Inc. for over five years, most recently as Senior Director of Finance, until the company was acquired by Bristol-Myers Squibb. Prior to joining Amylin, he held positions of increasing responsibility in finance and corporate strategy at Amgen, Inc. and at Baxter Healthcare Corporation. Jason is also a licensed professional engineer and has six years of experience in the environmental engineering industry.

Jason received his Bachelor of Science and Master of Science degrees in Civil Engineering from Stanford University and a Master of Business Administration from the Anderson School at the University of California, Los Angeles.

What is Jason A. Keyes' net worth?

The estimated net worth of Jason A. Keyes is at least $33,928.92 as of November 14th, 2024. Mr. Keyes owns 47,720 shares of Equillium stock worth more than $33,929 as of November 23rd. This net worth estimate does not reflect any other assets that Mr. Keyes may own. Learn More about Jason A. Keyes' net worth.

How old is Jason A. Keyes?

Mr. Keyes is currently 53 years old. There are 5 older executives and no younger executives at Equillium. The oldest executive at Equillium is Mr. Daniel Mark Bradbury, Executive Chairman, who is 63 years old. Learn More on Jason A. Keyes' age.

How do I contact Jason A. Keyes?

The corporate mailing address for Mr. Keyes and other Equillium executives is 2223 AVENIDA DE LA PLAYA SUITE 108, LA JOLLA CA, 92037. Equillium can also be reached via phone at (858) 240-1200 and via email at [email protected]. Learn More on Jason A. Keyes' contact information.

Has Jason A. Keyes been buying or selling shares of Equillium?

Jason A. Keyes has not been actively trading shares of Equillium during the past quarter. Learn More on Jason A. Keyes' trading history.

Who are Equillium's active insiders?

Equillium's insider roster includes Stephen Connelly (Insider), and Jason Keyes (CFO). Learn More on Equillium's active insiders.

Are insiders buying or selling shares of Equillium?

In the last twelve months, insiders at the sold shares 7 times. They sold a total of 87,324 shares worth more than $79,932.60. The most recent insider tranaction occured on November, 14th when CFO Jason A Keyes sold 10,000 shares worth more than $7,000.00. Insiders at Equillium own 30.3% of the company. Learn More about insider trades at Equillium.

Information on this page was last updated on 11/14/2024.

Jason A. Keyes Insider Trading History at Equillium

See Full Table

Jason A. Keyes Buying and Selling Activity at Equillium

This chart shows Jason A. Keyes's buying and selling at Equillium by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Equillium Company Overview

Equillium logo
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Read More

Today's Range

Now: $0.71
Low: $0.70
High: $0.74

50 Day Range

MA: $0.89
Low: $0.68
High: $1.38

2 Week Range

Now: $0.71
Low: $0.48
High: $3.25

Volume

53,877 shs

Average Volume

294,074 shs

Market Capitalization

$25.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.83